Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 44NIH 9NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 5Multiple Myeloma 4Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Vomiting 1Smoldering Multiple Myeloma 1Recurrence 1Ovarian Neoplasms 1Nausea 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Down Syndrome 1Brenner Tumor 1

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × auricularum × Clear all
NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
1,087 enrolled
Plasma cell

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

SWOG Cancer Research Network

Phase 3 Recruiting
510 enrolled
Plasma cell

Multiple Myeloma

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

SWOG Cancer Research Network

Phase 2 Completed
143 enrolled 14 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡